At a glance
ClinicalIndex Comparison RecordN/ACompleted· 123 enrolled
Drug / intervention
Emtricitabine/Tenofovir disoproxil fumarate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·interventional·Posted Jul 27, 2006·Updated Mar 20, 2018
In Brief
A clinical study evaluating Emtricitabine/Tenofovir disoproxil fumarate and Lopinavir/Ritonavir for HIV Infections. Completed, enrolled 123 participants across 5 sites in 5 countries.
Detailed Summary
Most anti-HIV regimens include a non-nucleoside reverse transcriptase inhibitor (NNRTI); however, some individuals fail on these regimens. The purpose of this study is to evaluate the safety and effectiveness of the protease inhibitor (PI) lopinavir/ritonavir (LPV/r) in HIV infected individuals who are failing an anti-HIV regimen that includes an NNRTI.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesIndia, Malawi, South Africa, Tanzania, Thailand
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartJan 2008
Primary CompletionOct 2010
Study CompletionMay 2012
TodayJul 2026
First PostedJul 27, 2006
Enrollment StartJan 1, 2008
Primary CompletionOct 1, 2010
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.9 years ago
Interventions
Emtricitabine/Tenofovir disoproxil fumaratedrug
Once daily
Lopinavir/Ritonavirdrug
Twice daily